stockrowSionna Therapeutics, Inc.
SION- EPS
- −61.0%
- Free cash flow
- −22.4%
Quarter to June 2026, against a year earlier
Follow SION
Alert me
Sionna Therapeutics, Inc. (SION) Return on invested capital
Sionna Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −125.0%, down 46.6 percentage points from fiscal 2025 (−78.4%). That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −78.4% | (78.38) |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | — |
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| INO Inovio Pharmaceuticals, Inc. compare | 0.00% |
| STRO Sutro Biopharma, Inc. compare | 0.00% |
| IPHA Innate Pharma S.A. Sponsored ADR compare | 0.00% |
| ANTX AN2 Therapeutics, Inc. compare | 0.00% |
| MGNX MacroGenics, Inc. compare | 0.00% |
| NGEN NervGen Pharma Corp. compare | 0.00% |
| CNTN Canton Strategic Holdings, Inc. compare | −8.11% |
| SION Sionna Therapeutics, Inc. | −125.0% |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)